Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0BXRDQ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Veltuzumab-SN-38
|
|||||
| Synonyms |
Vmab-SN-38
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 3 Indication(s)
B-cell lymphoma [ICD11:2A86]
Investigative
Burkitt lymphoma [ICD11:2A85]
Investigative
Mantle cell lymphoma [ICD11:2A85]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
6
|
|||||
| Antibody Name |
Veltuzumab
|
Antibody Info | ||||
| Antigen Name |
B-lymphocyte antigen CD20 (MS4A1)
|
Antigen Info | ||||
| Payload Name |
Active metabolite of irinotecan SN38
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
CL2A
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
Govitecan
|
|||||
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 0.83 nM | Moderate CD20 expression (CD20++) | ||
| Method Description |
Cytotoxicity was determined using the MTS dye reduction assay.
|
||||
| In Vitro Model | Follicular lymphoma | WSU-FSCCL cells | CVCL_1903 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 1.98 nM | High CD20 expression (CD20+++) | ||
| Method Description |
Cytotoxicity was determined using the MTS dye reduction assay.
|
||||
| In Vitro Model | Mantle cell lymphoma | JeKo-1 cells | CVCL_1865 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 4.88 nM | High CD20 expression (CD20+++) | ||
| Method Description |
Cytotoxicity was determined using the MTS dye reduction assay.
|
||||
| In Vitro Model | EBV-related Burkitt lymphoma | Raji cells | CVCL_0511 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 13.56 nM | High CD20 expression (CD20+++) | ||
| Method Description |
Cytotoxicity was determined using the MTS dye reduction assay.
|
||||
| In Vitro Model | Burkitt lymphoma | Daudi cells | CVCL_0008 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | > 50.00 nM | High CD20 expression (CD20+++) | ||
| Method Description |
Cytotoxicity was determined using the MTS dye reduction assay.
|
||||
| In Vitro Model | Burkitt lymphoma | Ramos cells | CVCL_0597 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | > 50.00 nM | Low CD20 expression (CD20+) | ||
| Method Description |
Cytotoxicity was determined using the MTS dye reduction assay.
|
||||
| In Vitro Model | B acute lymphoblastic leukemia | Reh cells | CVCL_1650 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | > 50.00 nM | Low CD20 expression (CD20+) | ||
| Method Description |
Cytotoxicity was determined using the MTS dye reduction assay.
|
||||
| In Vitro Model | Childhood B acute lymphoblastic leukemia | 697 cells | CVCL_0079 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | > 50.00 nM | Low CD20 expression (CD20+) | ||
| Method Description |
Cytotoxicity was determined using the MTS dye reduction assay.
|
||||
| In Vitro Model | Adult B acute lymphoblastic leukemia | RS4;11 cells | CVCL_0093 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | > 50.00 nM | Low CD20 expression (CD20+) | ||
| Method Description |
Cytotoxicity was determined using the MTS dye reduction assay.
|
||||
| In Vitro Model | Burkitt lymphoma | MN-60 cells | CVCL_1421 | ||
| Experiment 10 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 77.90 nM | Moderate CD22 expression (CD22++) | ||
| Method Description |
Cytotoxicity was determined using the MTS dye reduction assay.
|
||||
| In Vitro Model | B acute lymphoblastic leukemia | Reh cells | CVCL_1650 | ||
| Experiment 11 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 162 nM | Low CD20 expression (CD20+) | ||
| Method Description |
Cytotoxicity was determined using the MTS dye reduction assay.
|
||||
| In Vitro Model | B acute lymphoblastic leukemia | Reh cells | CVCL_1650 | ||
| Experiment 12 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 246.60 nM | High CD20 expression (CD20+++) | ||
| Method Description |
Cytotoxicity was determined using the MTS dye reduction assay.
|
||||
| In Vitro Model | EBV-related Burkitt lymphoma | Raji cells | CVCL_0511 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.